

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
GROSSMAN ET AL.


Serial No.: 09/596,114

Filed: **JUNE 16, 2000**

Title: **NOVEL VECTORS FOR IMPROVING
CLONING AND EXPRESSION IN
LOW COPY NUMBER PLASMIDS**

Examiner: LOEB, B.

Art Unit: 1636



I hereby certify that this correspondence is being deposited with the United States Postal Service as regular mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit 9/6/01

Signature M. Kapadia

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed copy of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the enclosed copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "William C. Coppola".

William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Docket No. HMR2050